Cipherome, Inc. is an AI and bioinformatics company based in San Jose, CA, specializing in personalized medicine and drug development. With their patented technology and extensive expertise in medicine, bioinformatics, and AI, they aim to address the issue of healthcare variability in drug response, which is estimated to be a $100 billion problem. Their Xentinel Compass Platform offers fast and easy analysis of large-scale genomic and clinical data, providing researchers with comprehensive functionalities for cohort selection, feature engineering, statistical analysis, machine learning, and visualization. Currently, Cipherome's platform is being utilized in personalized treatment for post-heart attack patients and diabetic-induced peripheral arterial disease in various locations across the United States.
Recently, Cipherome, Inc. was selected as a finalist in the prestigious American Heart Association For Health Technology Innovation competition, further highlighting their commitment to advancing healthcare technology. Through collaborations with university hospitals, research organizations, and global pharmaceutical companies, Cipherome aims to maximize the efficiency of genome-clinical data analysis and accelerate new drug development and treatment research. Their platform is designed to enhance researchers' accessibility to biobank data and provide the most efficient path to data insight, ultimately contributing to the improvement of precision medicine research competitiveness and capability.
Generated from the website